Your Article Summary
See Latest ArticlesManagement of superficial basal cell carcinoma: focus on imiquimod
Clinical, Cosmetic and Investigational Dermatology, 06/12/09
Raasch B - Imiquimod 5% cream has been shown to stimulate the innate and cell mediated immune system. The short-term success of imiquimod 5% cream in randomized controlled trials comparing different treatment regimes and dosing as a treatment for small superficial basal cell carcinoma (BCC) not on the face or neck is in the range of 82% for 5 times per week application. A high proportion of participants with good response rates to topical treatment (58%–92%) experience local side effects such as itching and burning, less commonly erosion and ulceration, but the proportion of participants ceasing treatment has not been high.
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Novel Therapies for Pemphigus Vulgaris: An Overview
Drugs & Aging, 09/21/09
Topical Pimecrolimus: A Review of its Use in the Management of Pediatric Atopic Dermatitis
Pediatric Drugs, 11/06/09
Clinical Importance of Purulence in Methicillin-Resistant Staphylococcus aureus Skin and Soft Tissue Infections
Journal of the American Board of Family Medicine, 11/09/09
Today in Dermatologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Childhood melanoma
Clinics in Dermatology, 11/04/09
Unusual variants of malignant melanoma
Clinics in Dermatology, 11/06/09
A Multimarker Prognostic Assay for Primary Cutaneous Melanoma
Clinical Cancer Research, 11/06/09
Today in Dermatopathology...keeping you current
Receive free subspecialty "5-minute updates" via email
Erysipeloid: a review
Clinical and Experimental Dermatology, 09/18/09
Update on oral lichen planus
Expert Review of Dermatology, 10/14/09
Childhood melanoma
Clinics in Dermatology, 11/04/09